Skip to main content

Table 1 Association of DAS over time with autoantibody levels over time

From: In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response

Outcome: DAS over time

n

β (95% CI) in DAS units per aU/mL

Anti-CCP2 IgG (0–1600)

259

1.1 × 10−4 (9.3 × 10−6 to 2.0 × 10−4)

Anti-CCP2 IgM (0–1400)

129

3.5 × 10−4 (1.4 × 10−4 to 5.7 × 10−4)

Anti-CCP2 IgA (0–1160)

128

3.6 × 10−4 (3.8 × 10−5 to 6.7 × 10−4)

RF IgM (0–200)

245

1.8 × 10−3 (8.2 × 10−4 to 2.8 × 10−3)

RF IgA (0–200)

188

7.9 × 10−4 (− 8.9 × 10−5 to 1.7 × 10−3)

Anti-CarP IgG (0–5272)

149

1.1 × 10−4 (4.1 × 10−5 to 1.7 × 10−4)

Anti-CarP IgM (0–3650)

128

1.7 × 10−4 (8.9 × 10−5 to 2.6 × 10−4)

Anti-CarP IgA (0–3100)

99

2.7 × 10−4 (1.6 × 10−4 to 3.8 × 10−4)

Anti-acetyl-lysine IgG (0–1000)

128

2.5 × 10−4 (2.1 × 10−5 to 4.7 × 10−4)

Anti-acetyl-ornithine IgG (0–1000)

226

2.0 × 10−4 (2.4 × 10−5 to 3.8 × 10−4)

Cit-Vim IgG (0–10,000)

188

3.7 × 10−5 (1.2 × 10−5 to 6.1 × 10−5)

Cit-Fib α IgG (0–25,000)

88

1.6 × 10−6 (− 2.0 × 10−5 to 2.3 × 10−5)

Cit-Fib β IgG (0–100,000)

191

4.2 × 10−6 (2.2 × 10−6 to 6.2 × 10−6)

Cit-Eno IgG (0–70,000)

105

2.9 × 10−6 (− 8.8 × 10−7 to 6.8 × 10−6)

  1. Generalized estimating equation of the continuous outcome DAS over the first year of treatment, within patients that were positive for that autoantibody at least once over the first year. Models were adjusted for age, gender, baseline HAQ, time, randomization arm at 4 months, and treatment decision at 8 months. Values beside the autoantibody names indicate range (in aU/mL)
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us